Cancer type†| Taiwanese population Incidence‡ | Incidence density (95%CI) of study cohort (per 10,000 person-years) | |||
---|---|---|---|---|---|
 |  | Non DM (n = 10491) | DM without medication (n = 8130) | DM without metformin (n = 4327) | DM with metformin (n = 11390) |
Total cancer | 49.9 | 46.0 (39.5-52.6)ab | 97.6 (86.9-108)ac | 91.7 (76.6-107)bd | 44.8 (38.6-51.0)cd |
   Male | 59.3 | 50.3 (41.0-59.6)ab | 122 (104-139)ac | 107 (84.9-130)bd | 47.7 (39.0-56.4)cd |
   Female | 41.2 | 41.0 (31.9-50.1)ab | 75.7 (62.6-88.8)ac | 74.0 (54.1-93.8)bd | 41.2 (32.4-50.1)cd |
Esophagus | 1.14 | 2.94 (1.28-4.60) | 5.14 (2.62-7.66) | 4.03 (0.81-7.26) | 4.78 (2.74-6.83) |
   Male | 2.09 | 3.63 (1.11-6.15) | 7.45 (3.05-11.9) | 5.09 (0.10-10.1) | 5.83 (2.78-8.89) |
   Female | 0.20 | 2.13 (0.04-4.21) | 3.05 (0.38-5.73) | 2.84 (-1.10-6.78) | 3.52 (0.91-6.13) |
Stomach | 2.64 | 3.91 (1.99-5.83) | 5.14 (2.62-7.66) | 6.71 (2.55-10.9) | 5.46 (3.28-7.65) |
   Male | 3.49 | 3.63 (1.12-6.15) | 6.78 (2.58-11.0) | 8.90 (2.31-15.5) | 4.58 (1.88-7.29) |
   female | 1.86 | 4.23 (1.30-7.17) | 3.67 (0.73-6.60) | 4.26 (-0.56-9.09) | 6.53 (2.98-10.1) |
Colorectal | 7.31 | 7.07 (4.50-9.64)ab | 19.8 (14.9-24.8)ac | 17.4 (10.7-24.1)bd | 6.83 (4.39-9.27)cd |
   Male | 8.63 | 6.78 (3.35-10.2)a | 23.6 (15.8-31.4)ab | 12.7 (4.83-20.6) | 9.57 (5.66-13.5)b |
   female | 6.06 | 7.40 (3.53-11.3)a | 16.4 (10.2-22.6)b | 22.6 (11.6-33.7)ac | 3.52 (0.91-6.12)bc |
Liver | 6.55 | 5.88 (3.53-8.23)ab | 24.3 (18.8-29.7)ac | 18.7 (11.8-25.7)b | 10.2 (7.24-13.2)c |
   Male | 9.25 | 8.64 (4.76-12.5)ab | 32.3 (23.2-41.4)ac | 29.1 (17.2-41.0)bd | 12.5 (8.01-16.9)cd |
   Female | 3.90 | 2.65 (0.33-4.98)a | 17.0 (10.7-23.3)a | 7.10 (0.88-13.3) | 7.54 (3.72-11.3) |
Pancreas | 0.99 | 2.45 (0.93-3.96) | 5.14 (2.62-7.66) | 4.70 (1.22-8.18) | 4.78 (2.74-6.83) |
   Male | 1.17 | 2.72 (0.54-4.90) | 5.42 (1.67-9.18) | 5.09 (0.10-10.1) | 5.41 (2.47-8.36) |
   female | 0.81 | 2.13 (0.04-4.21) | 4.88 (1.50-8.27) | 4.26 (-0.56-9.09) | 4.02 (1.24-6.81) |